About the Company
We do not have any company description for Omega Therapeutics, Inc. at the moment.
Exchange
OTC
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest News on Omega Therapeutics, Inc.
Omega Therapeutics Reports Third Quarter 2024 Results
Omega Therapeutics, Inc. is a biotechnology company focused on developing programmable epigenomic mRNA medicines using its OMEGA platform, operating primarily in the biotechnology sector.
Omega Therapeutics Reports Second Quarter 2024 ... - Seeking Alpha
Omega Therapeutics Reports Second Quarter 2024 Financial Results and Highlights Recent Company Progress Aug. 06, 2024 7:00 AM ET Omega Therapeutics, Inc. (OMGAQ) ...
Omega Therapeutics Announces Successful Completion of Phase 1 ... - Nasdaq
--Omega Therapeutics, Inc., a biotechnology company pioneering the development of a new class of programmable epigenomic medicines, today announced financial results for the quarter ended ...
Omega Therapeutics Announces Jennifer Nelson, Ph.D., as Senior Vice ...
Contact Investor contact: Eva Stroynowski 617.949.4370 estroynowski@omegatx.com Media contact: Jason Braco 646.751.4361 jbraco@lifescicomms.com Source: Omega Therapeutics 2024 GlobeNewswire, Inc.
Omega Therapeutics to Participate in the H.C. Wainwright 4th Annual ...
CAMBRIDGE, Mass., Dec. 04, 2023 (GLOBE NEWSWIRE) -- Omega Therapeutics, Inc. (Nasdaq: OMGA) (“Omega”), a clinical-stage biotechnology company pioneering the development of a new class of ...
Omega Therapeutics Presents New Preclinical Data Supporting the ...
CAMBRIDGE, Mass., Oct. 16, 2023 (GLOBE NEWSWIRE) -- Omega Therapeutics, Inc. (Nasdaq: OMGA) (“Omega”), a clinical-stage biotechnology company pioneering the development of a new class of ...
Omega Therapeutics Inc. (OMGA) Stock Price Today - WSJ
View the latest Omega Therapeutics Inc. (OMGA) stock price, news, historical charts, analyst ratings and financial information from WSJ.
Omega Therapeutics' Cancer Program Shows Encouraging Anti Tumor ...
Omega Therapeutics Inc (NASDAQ: OMGA) announced preliminary data from the initial two dose level cohorts (n=8) from Part 1 of its Phase 1/2 MYCHELANGELO I study of OTX-2002 in hepatocellular ...
Similar Companies
Loading the latest forecasts...